

C34-A3  
Vol. 29 No. 27  
Replaces C34-A2  
Vol. 20 No. 14

---

# Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition

This document addresses appropriate methods of collection and analysis, quality control, and the evaluation and reporting of test results.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



# Clinical and Laboratory Standards Institute

*Advancing Quality in Health Care Testing*

Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the health care community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related health care issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and health care services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

## **PUBLICATIONS**

A document is published as a standard, guideline, or committee report.

**Standard** A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

**Guideline** A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

**Report** A document that has not been subjected to consensus review and is released by the Board of Directors.

## **CONSENSUS PROCESS**

The CLSI voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most documents are subject to two levels of consensus—“proposed” and “approved.” Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

**Proposed** A consensus document undergoes the first stage of review by the health care community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

**Approved** An approved standard or guideline has achieved consensus within the health care community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (ie, that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI’s established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

## **COMMENTS**

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

## **VOLUNTEER PARTICIPATION**

Health care professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at [customerservice@clsi.org](mailto:customerservice@clsi.org) or +610.688.0100 for additional information on committee participation.

C34-A3  
ISBN 1-56238-713-8  
ISSN 0273-3099

Volume 29 Number 27

---

## Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition

Vicky A. LeGrys, DrA, MT(ASCP)  
Robert Applequist  
Dennis R. Briscoe  
Phillip Farrell, MD, PhD  
Rosetta Hickstein, MT(ASCP)  
Stanley F. Lo, PhD, DABCC, FACB  
Rosa Passarell  
Douglas W. Rheinheimer, MT  
Beryl J. Rosenstein, MD  
Jeffrey E. Vaks, PhD

### Abstract

Clinical and Laboratory Standards Institute document C34-A3—*Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition* is a guideline for the performance of the sweat test for the diagnosis of cystic fibrosis. The primary audience includes laboratory and clinical personnel responsible for collecting, analyzing, reporting, and evaluating sweat test results. Sweat stimulation, collection, and the quantitative measurement of sweat chloride are described along with quality assurance and result evaluation.

Clinical and Laboratory Standards Institute (CLSI). *Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition*. CLSI document C34-A3 (ISBN 1-56238-713-8). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI/NCCLS documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org)



Copyright ©2009 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute (“CLSI”).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

### **Suggested Citation**

CLSI. *Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition*. CLSI document C34-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.

### **Proposed Guideline**

March 1993

### **Approved Guideline**

December 1994

### **Approved Guideline—Second Edition**

June 2000

### **Approved Guideline—Third Edition**

December 2009

ISBN 1-56238-713-8  
ISSN 0273-3099

## Committee Membership

### Area Committee on Clinical Chemistry and Toxicology

**David A. Armbruster, PhD,  
DABCC, FACB  
Chairholder  
Abbott Diagnostics  
Abbott Park, Illinois, USA**

**David G. Grenache, PhD,  
MT(ASCP), DABCC, FACB  
Vice-Chairholder  
University of Utah, ARUP  
Laboratories  
Salt Lake City, Utah, USA**

David M. Bunk, PhD  
National Institute of Standards and  
Technology  
Gaithersburg, Maryland, USA

Steven C. Kazmierczak, PhD,  
DABCC, FACB  
Department of Pathology  
Oregon Health and Science  
University  
Portland, Oregon, USA

Loralie J. Langman, PhD  
Mayo Clinic  
Rochester, Minnesota, USA

Jeffrey E. Vaks, PhD  
Roche Molecular Diagnostics  
Pleasanton, California, USA

Hubert Vesper, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

### Subcommittee on Sweat Testing

**Vicky A. LeGrys, DrA,  
MT(ASCP)  
Chairholder  
Univ. of North Carolina School of  
Medicine  
Chapel Hill, North Carolina, USA**

Robert Applequist  
Labconco Corp  
Kansas City, Missouri, USA

Dennis R. Briscoe  
Wescor, Inc.  
Logan, Utah, USA

Phillip Farrell, MD, PhD  
University of Wisconsin  
Madison, Wisconsin, USA

Graham Henderson White, PhD  
Flinders Medical Centre  
Bedford Park  
Australia

Jack Zakowski, PhD, FACB  
Beckman Coulter, Inc.  
Brea, California, USA

#### Advisors

John Rex Astles, PhD, FACB  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

Greg Cooper, CLS, MHA  
Bio-Rad Laboratories, Inc., QSD  
Division  
Plano, Texas, USA

Paul D'Orazio, PhD  
Instrumentation Laboratory  
Bedford, Massachusetts, USA

Carl C. Garber, PhD, FACB  
Quest Diagnostics, Incorporated  
Madison, New Jersey, USA

Uttam Garg, PhD, DABCC  
Children's Mercy Hospitals and  
Clinics  
Kansas City, Missouri, USA

Claude Giroud, PhD  
Bio-Rad Laboratories, Inc.  
Marnes-La-Coquette, France

Neil Greenberg, PhD  
Ortho-Clinical Diagnostics, Inc.  
Rochester, New York, USA

Christopher M. Lehman, MD  
Univ. of Utah Health Sciences  
Center  
Salt Lake City, Utah, USA

W. Gregory Miller, PhD  
Virginia Commonwealth University  
Richmond, Virginia, USA

Gary L. Myers, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

David Sacks, MD  
Brigham and Women's Hospital  
and Harvard Medical School  
Boston, Massachusetts, USA

Thomas L. Williams, MD  
Nebraska Methodist Hospital  
Omaha, Nebraska, USA

Rosetta Hickstein, MT(ASCP)  
All Children's Hospital  
St. Petersburg, Florida, USA

Stanley F. Lo, PhD, DABCC,  
FACB  
Children's Hospital of Wisconsin  
Milwaukee, Wisconsin, USA

Rosa Passarell  
TECIL  
Barcelona, Spain

Douglas W. Rheinheimer, MT  
FDA Ctr. for Devices/Rad. Health  
Rockville, Maryland, USA

Beryl J. Rosenstein, MD  
Johns Hopkins University School of  
Medicine  
Baltimore, Maryland, USA

Jeffrey E. Vaks, PhD  
Roche Molecular Diagnostics  
Pleasanton, California, USA

#### Advisors

Ronda Greaves, PhD, MAACB,  
MAppSc  
Royal Children's Hospital  
Victoria, Australia

Paul Griffiths, DipCB, FRCPath,  
MBA  
Birmingham Children's Hospital  
Birmingham, United Kingdom

**Staff**

Clinical and Laboratory Standards  
Institute  
Wayne, Pennsylvania, USA

Lois M. Schmidt, DA  
*Vice President, Standards  
Development and Marketing*

David E. Sterry, MT(ASCP)  
*Staff Liaison*

Patrice E. Polgar  
*Project Manager*

Melissa A. Lewis, ELS  
*Editorial Manager*

Carol DiBerardino, MLA, ELS  
*Assistant Editor*

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Standard Precautions.....	1
3 Terminology.....	1
3.1 A Note on Terminology.....	1
3.2 Definitions.....	2
3.3 Abbreviations and Acronyms.....	6
4 Procedural Precautions.....	6
4.1 Chemical Hygiene.....	6
4.2 Verification of Measurement Procedures.....	6
4.3 Burns.....	7
4.4 Electrical Malfunctions.....	8
4.5 Allergic Reactions.....	8
5 Principle.....	9
5.1 Sweat Stimulation.....	9
5.2 Sweat Collection.....	9
5.3 Measurement of Chloride in Sweat.....	10
6 Apparatus and Equipment.....	10
6.1 Iontophoresis Equipment.....	11
6.2 Chloridometer.....	12
7 Materials and Reagents.....	12
7.1 Iontophoresis Materials.....	12
7.2 Sweat Collection Supplies.....	13
7.3 Chloride Determination by Chloridometer.....	13
8 Sweat Stimulation and Collection Procedures.....	14
8.1 Patient Education.....	14
8.2 Effects of Patient Age.....	15
8.3 Collection Timing and Sites.....	15
8.4 Stimulation and Collection of Sweat on Gauze or Filter Paper.....	16
8.5 Microbore Tubing Collector Stimulation and Collection Procedure.....	19
8.6 Procedural Notes and Precautions for Stimulation and Collection.....	20
8.7 Sample Requirements.....	21
9 Analysis of Sweat Chloride by Titration With a Chloridometer.....	22
9.1 Principle.....	22
9.2 Specimen Stability and Storage.....	22
9.3 Procedure Using Gauze or Filter Paper Collection.....	23
9.4 Procedure Using Microbore Tubing Collection.....	24
9.5 Result Reporting.....	25
9.6 Procedural Notes and Precautions.....	25
9.7 Method Validation.....	26

**Contents (Continued)**

10	Sweat Conductivity.....	27
11	Labeling of Containers.....	27
11.1	Reagents, Calibrators, and Controls.....	27
11.2	Weighing Vials and Specimen Containers.....	27
11.3	Titration Vials.....	27
12	Quality Control and Quality Assurance.....	28
12.1	Analytical Quality Control.....	28
12.2	Quality Assurance.....	28
12.3	Continuous Quality Monitoring.....	29
13	Evaluation of Results.....	29
13.1	Diagnostic Criteria.....	29
13.2	Recommended Reference Intervals for Sweat Chloride.....	29
13.3	Transient Elevation in Sweat Electrolyte Concentrations.....	30
13.4	Intermediate Sweat Chloride Concentrations.....	30
13.5	Repeat Sweat Chloride Determination.....	31
13.6	Other Diseases Associated With Elevated Sweat Electrolyte Concentrations.....	31
13.7	Sources of Error.....	31
	References.....	33
	Appendix A. Indications for Sweat Testing.....	36
	Appendix B. Current Density.....	37
	Appendix C. Concentration of Pilocarpine Nitrate.....	38
	Appendix D. Reported Diseases or Conditions Other Than Cystic Fibrosis Associated With an Elevated Sweat Electrolyte Concentration.....	39
	Summary of Consensus Comments and Subcommittee Responses.....	40
	Summary of Delegate Comments and Subcommittee Responses.....	42
	The Quality Management System Approach.....	48
	Related CLSI Reference Materials.....	49

## Foreword

The quantitative measurement of chloride in sweat (commonly called the “sweat test”) is used to confirm the diagnosis of cystic fibrosis (CF). With an approximate incidence of 1:3200, CF is the most common life-threatening genetic disease within the white population. It is an autosomal recessive disorder characterized by viscous secretions that affect the exocrine glands, primarily in the lungs and pancreas. Patients with CF have an increased concentration of sodium, chloride, and potassium in their sweat. The criteria for the diagnosis of CF include the presence of one or more characteristic phenotypic features, or a history of CF in a sibling, or a positive newborn screening test result; and an increased sweat chloride concentration by pilocarpine iontophoresis on two or more occasions, or identification of two CF-causing mutations or demonstration of abnormal nasal epithelial ion transport.<sup>1,2</sup>

The sweat test has been reported to have unacceptably high false-positive (up to 15%) and false-negative (up to 12%) rates attributable to inaccurate methodology, technical error, and patient physiology.<sup>3-8</sup> Comprehensive guidelines addressing the collection of sweat and the quantitative measurement of chloride in sweat are needed. Improvement in the performance of such tests can only occur when laboratory scientists and clinicians are aware of appropriate methods of collection and analysis, quality control, and evaluation of results. This document describes, in detail, the quantitative pilocarpine iontophoresis test for the determination of sweat chloride, including techniques to minimize the potential for false-positive and false-negative test results. Screening methods based on sweat conductivity are also mentioned. Other methods for measuring sweat electrolytes after pilocarpine iontophoresis exist but are not included in the guideline. Some of these methods are documented as having significant analytical problems.<sup>3-8</sup>

The Cystic Fibrosis Foundation requires that, at accredited Cystic Fibrosis Care Centers for diagnosis, sweating be stimulated by pilocarpine iontophoresis and collected in either gauze or filter paper, or microbore tubing followed by quantitative measurement of chloride.<sup>2</sup> At alternative sites, as a screening procedure, conductivity may be measured (see Section 10). Patients with a sweat conductivity value of 50 mmol/L (equivalent NaCl) or above should have a quantitative measurement of sweat chloride.<sup>9,10</sup>

This edition replaces the second edition approved guideline, C34-A2, which was published in 2000. Several changes have been made in this edition, including the following additions: a microvolume chloride procedure for sweat collected in coils; storage conditions for sweat; new reference ranges for infants; suggestions for enhancing sweat collection volume. It also includes sections on method validation and on developing and monitoring quality assurance and quality control.

## Key Words

Chloridometer, iontophoresis, sweat chloride, sweat testing



# Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition

## 1 Scope

The following procedures are described: the stimulation and collection of sweat and the quantitative measurement of chloride; sweat stimulation by pilocarpine iontophoresis (specific precautions are noted); and sweat collection in filter paper, gauze, and microbore tubing. Sweat chloride ( $\text{Cl}^-$ ) determination is described using coulometric titration. Screening methods based on sweat conductivity are also mentioned. Other methods for measuring sweat electrolytes after pilocarpine iontophoresis exist but are not included in the guideline. Some of these methods are documented as having significant analytical problems and also have limited diagnostic application.<sup>3-8</sup> Validation studies and quality assurance (QA) techniques are discussed, along with analytical and biological sources of error. The evaluation of sweat chloride test results to include reference intervals and diagnostic criteria are described, with an emphasis on the application of sweat chloride testing to newborn screening for cystic fibrosis (CF). This document is primarily directed towards laboratory and clinical personnel responsible for collecting, analyzing, reporting, and evaluating sweat chloride test results.

Because the sweat test has been reported to have unacceptably high false-positive and false-negative rates attributable to inaccurate methodology, technical error, and patient physiology,<sup>3-8</sup> comprehensive guidelines addressing the collection of sweat and the quantitative measurement of chloride in sweat are needed. Improvement in the performance of such tests can only occur when laboratory scientists and clinicians are aware of appropriate methods of collection and analysis, quality control (QC), and evaluation of results. This document describes, in detail, the quantitative pilocarpine iontophoresis test for the determination of sweat chloride, including techniques to minimize the potential for false-positive and false-negative test results.

## 2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention.<sup>11</sup> For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.<sup>12</sup>

Currently, standard precautions for protection from transmissible infectious agents exempt sweat unless it contains visible blood. However, it is recommended that laboratory personnel wear powder-free gloves during sweat collection and analysis as routine practice, both for their protection and to prevent contamination of the sample.<sup>11</sup>

## 3 Terminology

### 3.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the